Tumor protective activity of CD4+ but Not of CD8+ T cells in DNA-vaccinated mice challenged with bcr-abl-transformed cells

Clinical and Developmental Immunology

Volumn 2013, Issue , 2013, Pages

  Petráčková, Martina ^a   Lučanský, Vincent ^a   Vonka, Vladimír ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CD4 ANTIBODY; DNA VACCINE; FAS ANTIGEN; FAS LIGAND; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; CANCER VACCINE; HLA ANTIGEN CLASS 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN RECOGNITION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROTECTION; CELL SURFACE; CELL TRANSFORMATION; CONTROLLED STUDY; DNA IMMUNIZATION; EFFECTOR CELL; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; STATISTICAL SIGNIFICANCE; ANIMAL; CYTOLOGY; DISEASE MODEL; GENETICS; HUMAN; IMMUNIZATION; IMMUNOLOGY; LYMPHOCYTE DEPLETION; METABOLISM; MORTALITY; NEOPLASM; SPLEEN; TRANSFORMED CELL LINE;

ANIMALS; ANTIGENS, CD95; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TRANSFORMED; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; FAS LIGAND PROTEIN; FEMALE; FUSION PROTEINS, BCR-ABL; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNIZATION; LYMPHOCYTE DEPLETION; MICE; NEOPLASMS; SPLEEN; VACCINES, DNA;

EID: 84890020972     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2013/923107     Document Type: Article

References (29)

1. Kennedy R., Celis E., Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunological Reviews 2008 222 129 144 10.1111/j. 1600-065X.2008.00616.x.:129-44 (Pubitemid 351430378)
2. Thibodeau J., Bourgeois-Daigneault M. C., Lapointe R., Targeting the MHC Class II antigen presentation pathway in cancer immunotherapy. Oncoimmunology 2012 1 6 908 916
3. Perez-Diez A., Joncker N. T., Choi K., Chan W. F. N., Anderson C. C., Lantz O., Matzinger P., CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 2007 109 12 5346 5354 2-s2.0-34249990107 10.1182/blood-2006-10- 051318 (Pubitemid 46890556)
4. van de Berg P. J., van Leeuwen E. M., ten Berge I. J., van Lier R., Cytotoxic human CD4+ T cells. Current Opinion in Immunology 2008 20 3 339 343 2-s2.0-45449120804 10.1016/j.coi.2008.03.007
5. Appay V., The physiological role of cytotoxic CD4+ T-cells: the holy grail? Clinical and Experimental Immunology 2004 138 1 10 13 2-s2.0-4644234449 10.1111/j.1365-2249.2004.02605.x (Pubitemid 39279959)
6. Marshall N. B., Swain S. L., Cytotoxic CD4 T cells in antiviral immunity. Journal of Biomedicine and Biotechnology 2011 2011 954602 10.1155/2011/954602
7. Namekawa T., Wagner U. G., Goronzy J. J., Weyand C. M., Functional subsets of CD4 T cells in rheumatoid synovitis. Arthritis and Rheumatism 1998 41 12 2108 2116 (Pubitemid 29009368)
8. Porakishvili N., Kardava L., Jewell A. P., Yong K., Glennie M. J., Akbar A., Lydyard P. M., Cytotoxic CD4+ T cells in patients with B cell chronic lymphocytic leukemia kill via a perforin-mediated pathway. Haematologica 2004 89 4 435 443 2-s2.0-2942707572 (Pubitemid 38798548)
9. Yasukawa M., Ohminami H., Arai J., Kasahara Y., Ishida Y., Fujita S., Granule exocytosis, and not the Fas/Fas ligand system, is the main pathway of cytotoxicity mediated by alloantigen-specific CD4+ as well as CD8+ cytotoxic T lymphocytes in humans. Blood 2000 95 7 2352 2355 2-s2.0-0034176232 (Pubitemid 30167735)
10. Echchakir H., Bagot M., Dorothée G., Martinvalet D., le Gouvello S., Boumsell L., Chouaib S., Bensussan A., Mami-Chouaib F., Cutaneous T cell lymphoma reactive CD4+ cytotoxic T lymphocyte clones display a Th1 cytokine profile and use a Fas-independent pathway for specific tumor cell lysis. Journal of Investigative Dermatology 2000 115 1 74 80 2-s2.0-0033909601 10.1046/j.1523-1747.2000.00995.x (Pubitemid 30470195)
11. Lucansky V., Sobotkova E., Tachezy R., Duskova M., Vonka V., DNA vaccination against bcr-abl-positive cells in mice. International Journal of Oncology 2009 35 4 941 951 2-s2.0-70449434669 10.3892/ijo-00000408
12. McLaughlin J., Chianese E., Witte O. N., In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome. Proceedings of the National Academy of Sciences of the United States of America 1987 84 18 6558 6562 2-s2.0-0023410428
13. Petráčková M., Tachezy R., Vonka V., Properties of bcr-abl-transformed mouse 12B1 cells secreting interleukin-2 and granulocyte-macrophage colony-stimulating factor. I: derivation, genetic stability, oncogenicity and immunogenicity. International Journal of Oncology 2012 40 5 1668 1676 2-s2.0-84860296173 10.3892/ijo.2012.1365
14. Šmahel M., Šíma P., Ludvíková V., Vonka V., Modified HPV16 E7 genes as DNA vaccine against E7-containing oncogenic cells. Virology 2001 281 2 231 238 2-s2.0-0035866607 10.1006/viro.2000.0794 (Pubitemid 32881139)
15. Aldrich J. F., Lowe D. B., Shearer M. H., Winn R. E., Jumper C. A., Bright R. K., Kennedy R. C., CD4+ T lymphocytes are critical mediators of tumor immunity to simian virus 40 large tumor antigen induced by vaccination with plasmid DNA. Journal of Virology 2011 85 14 7216 7224 2-s2.0-79960385536 10.1128/JVI.00543-11
16. Bright R. K., Shearer M. H., Kennedy R. C., Immunization of BALB/c mice with recombinant simian virus 40 large tumor antigen induces antibody-dependent cell-mediated cytotoxicity against simian virus 40-transformed cells: an antibody-based mechanism for tumor immunity. Journal of Immunology 1994 153 5 2064 2071 2-s2.0-0028023528
17. Lowe D. B., Shearer M. H., Jumper C. A., Bright R. K., Kennedy R. C., Tumor immunity against a simian virus 40 oncoprotein requires CD8 + T lymphocytes in the effector immune phase. Journal of Virology 2010 84 2 883 893 2-s2.0-73849101055 10.1128/JVI.01512-09
18. Mumberg D., Monach P. A., Wanderling S., Philip M., Toledano A. Y., Schreiber R. D., Schreiber H., CD4+ T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN- γ Proceedings of the National Academy of Sciences of the United States of America 1999 96 15 8633 8638 2-s2.0-0033587720 10.1073/pnas.96.15.8633 (Pubitemid 29354843)
19. Hagn M., Sontheimer K., Dahlke K., Brueggemann S., Kaltenmeier C., Beyer T., Hofmann S., Lunov O., Barth T. F., Fabricius D., Tron K., Nienhaus G. U., Simmet T., Schrezenmeier H., Jahrsdörfer B., Human B cells differentiate into granzyme B-secreting cytotoxic B lymphocytes upon incomplete T-cell help. Immunology and Cell Biology 2012 90 4 457 467 2-s2.0-84859947465 10.1038/icb.2011.64
20. Balsamo M., Pietra G., Vermi W., Moretta L., Mingari M. C., Vitale M., Melanoma immunoediting by NK cells. Oncoimmunology 2012 1 9 1607 1609
21. Fruci D., Lo M. E., Cifaldi L., T and NK cells: two sides of tumor immunoevasion. Journal of Translational Medicine 2013 11, article 30 10.1186/1479-5876-11-30.:30-11
22. Serody J. S., Brecher M. E., Dent G., Bentley S. A., Frelinger J. A., Shea T. C., A method for the production of CD4+ chronic myelogenous leukemia-specific allogeneic T lymphocytes. Cancer Research 1997 57 8 1547 1553 2-s2.0-0030907467 (Pubitemid 27175573)
23. Jiang Y.-Z., Mavroudis D., Dermime S., Hensel N., Couriel D., Molldrem J., Barrett A. J., Alloreactive CD4+ T lymphocytes can exert cytotoxicity to chronic myeloid leukaemia cells processing and presenting exogenous antigen. British Journal of Haematology 1996 93 3 606 612 2-s2.0-0029888468 (Pubitemid 26168606)
24. Alyea E. P., Soiffer R. J., Canning C., Neuberg D., Schlossman R., Pickett C., Collins H., Wang Y., Anderson K. C., Ritz J., Toxicity and efficacy of defined doses of CD4+ donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood 1998 91 10 3671 3680 2-s2.0-20244374668 (Pubitemid 28225734)
25. Dodi I., Van Rhee F., Forde H., Roura-Mir C., Jaraquemada D., Goldman J., Madrigal J., CD4+ bias in T cells cloned from a CML patient with active graft versus leukemia effect. Cytotherapy 2002 4 4 353 363 2-s2.0-0036382017 10.1080/146532402760271145
26. Chen C. L.-U., Maecker H. T., Lee P. P., Development and dynamics of robust T-cell responses to CML under imatinib treatment. Blood 2008 111 11 5342 5349 2-s2.0-45749101780 10.1182/blood-2007-12-128397
27. Ten Bosch G. J. A., Toornvliet A. C., Friede T., Melief C. J. M., Leeksma O. C., Recognition of peptides corresponding to the joining region of p210(BCR-ABL) protein by human T cells. Leukemia 1995 9 8 1344 1348 2-s2.0-0029092733
28. Yasukawa M., Ohminami H., Kaneko S., Yakushijin Y., Nishimura Y., Inokuchi K., Miyakuni T., Nakao S., Kishi K., Kubonishi I., Dan K., Fujita S., CD4+ cytotoxic T-cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-restricted manner. Blood 1998 92 9 3355 3361 2-s2.0-0032213388 (Pubitemid 28492344)
29. Hirschhorn-Cymerman D., Budhu S., Kitano S., Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype. Journal of Experimental Medicine 2012 209 11 2113 2126